BioNexus Gene Lab Corp. (BGLC)
Oxford Ledge is still expanding full research coverage of BGLC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BioNexus operates chemical distribution and genomic screening businesses in Southeast Asia while expanding into cancer detection diagnostics through a licensing arrangement.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-05
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-K Annual financial report with audited statements 2026-04-14
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-03-17
- 8-K Other material event; Financial statements and exhibits 2026-02-23
Source: SEC EDGAR.
- Open BGLC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.